Floatz logo

Tas-102

Neuroendocrine Tumor

University of Wisconsin, MadisonunclassifiedPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Calcium folinate pentahydrate
ITM Solucin GmbH
Phase 3BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 3BB
Pasireotide
RECORDATI GROUP
Phase 4BB

View all 9 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →